Paper37795443
The potential and challenges of targeting MTAP-negative cancers beyond synthetic lethality.
Bray C and 3 others. Front Oncol, 2023. Cited by 34 papers, by iCite.
Cite this record
ConductScience Library. The potential and challenges of targeting MTAP-negative cancers beyond synthetic lethality. Papers, record 37795443. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37795443
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The potential and challenges of targeting MTAP-negative cancers beyond synthetic lethality.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References111
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 11343899 | Spliceosomal UsnRNP biogenesis, structure and function. | Curr Opin Cell Biol | 2001 | https://conductscience.org/library/papers/11343899 | PubMed |
| 2 | 20164920 | The landscape of somatic copy-number alteration across human cancers. | Nature | 2010 | https://conductscience.org/library/papers/20164920 | PubMed |
| 3 | 32025013 | The evolutionary history of 2,658 cancers. | Nature | 2020 | https://conductscience.org/library/papers/32025013 | PubMed |
| 4 | 34780697 | Human Mat2A Uses an Ordered Kinetic Mechanism and Is Stabilized but Not Regulated by Mat2B. | Biochemistry | 2021 | https://conductscience.org/library/papers/34780697 | PubMed |
| 5 | 6781742 | Abnormal regulation of methylthioadenosine and polyamine metabolism in methylthioadenosine phosphorylase-deficient human leukemic cell lines. | Cancer Res | 1980 | https://conductscience.org/library/papers/6781742 | PubMed |
| 6 | 8616780 | Codeletion of the genes for p16INK4, methylthioadenosine phosphorylase, interferon-alpha1, interferon-beta1, and other 9p21 markers in human malignant cell lines. | Cancer Genet Cytogenet | 1996 | https://conductscience.org/library/papers/8616780 | PubMed |
| 7 | 22143770 | Structural insights into protein arginine symmetric dimethylation by PRMT5. | Proc Natl Acad Sci U S A | 2011 | https://conductscience.org/library/papers/22143770 | PubMed |
| 8 | 31408619 | Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation. | Cancer Cell | 2019 | https://conductscience.org/library/papers/31408619 | PubMed |
| 9 | 35264604 | MTAP loss correlates with an immunosuppressive profile in GBM and its substrate MTA stimulates alternative macrophage polarization. | Sci Rep | 2022 | https://conductscience.org/library/papers/35264604 | PubMed |
| 10 | 28238654 | PRMT5-Dependent Methylation of the TIP60 Coactivator RUVBL1 Is a Key Regulator of Homologous Recombination. | Mol Cell | 2017 | https://conductscience.org/library/papers/28238654 | PubMed |
| 11 | 24969958 | MTAP is an independent prognosis marker and the concordant loss of MTAP and p16 expression predicts short survival in non-small cell lung cancer patients. | Eur J Surg Oncol | 2014 | https://conductscience.org/library/papers/24969958 | PubMed |
| 12 | 22327218 | Arginine methylation controls growth regulation by E2F-1. | EMBO J | 2012 | https://conductscience.org/library/papers/22327218 | PubMed |
| 13 | 22446626 | DBIRD complex integrates alternative mRNA splicing with RNA polymerase II transcript elongation. | Nature | 2012 | https://conductscience.org/library/papers/22446626 | PubMed |
| 14 | 31611688 | PRMT5 methylome profiling uncovers a direct link to splicing regulation in acute myeloid leukemia. | Nat Struct Mol Biol | 2019 | https://conductscience.org/library/papers/31611688 | PubMed |
| 15 | 17709427 | Two distinct arginine methyltransferases are required for biogenesis of Sm-class ribonucleoproteins. | J Cell Biol | 2007 | https://conductscience.org/library/papers/17709427 | PubMed |
| 16 | 23363077 | Fluorinated N,N-dialkylaminostilbenes repress colon cancer by targeting methionine S-adenosyltransferase 2A. | ACS Chem Biol | 2013 | https://conductscience.org/library/papers/23363077 | PubMed |
| 17 | 3093064 | Methylthioadenosine phosphorylase deficiency in human leukemias and solid tumors. | Cancer Res | 1986 | https://conductscience.org/library/papers/3093064 | PubMed |
| 18 | 28977470 | The PRMT5/WDR77 complex regulates alternative splicing through ZNF326 in breast cancer. | Nucleic Acids Res | 2017 | https://conductscience.org/library/papers/28977470 | PubMed |
| 19 | 33450196 | MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage. | Cancer Cell | 2021 | https://conductscience.org/library/papers/33450196 | PubMed |
| 20 | 21074527 | Histone arginine methylation. | FEBS Lett | 2011 | https://conductscience.org/library/papers/21074527 | PubMed |
Cited by28
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 34 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42938892 | MTAP Loss and Pleural Mesothelioma (PM): Current Treatment Strategies and Emerging Therapeutic Approaches. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42938892 | PubMed |
| 42723945 | Case Report: Targeting EGFR exon 20 insertion and MTAP loss in refractory metastatic upper tract urothelial carcinoma. | Front Oncol | 2026 | https://conductscience.org/library/papers/42723945 | PubMed |
| 42436136 | Specimen quality shapes the actionable genomic landscape in comprehensive cancer genomic profiling. | NPJ Genom Med | 2026 | https://conductscience.org/library/papers/42436136 | PubMed |
| 42421155 | Tumor-type specific methylation patterns of MTAP in human samples and cell lines. | Clin Epigenetics | 2026 | https://conductscience.org/library/papers/42421155 | PubMed |
| 42374173 | Prevalence of heterozygous and homozygous 9p21 deletions in human cancer: a tissue microarray study on 4,999 tumors from 125 different tumor types. | Mol Med | 2026 | https://conductscience.org/library/papers/42374173 | PubMed |
| 42129334 | MTAP loss in gastrointestinal cancers is associated with CDKN2A deletion, poor prognosis in gastric carcinoma, and potential relevance for PRMT5-targeted therapy. | Sci Rep | 2026 | https://conductscience.org/library/papers/42129334 | PubMed |
| 42092301 | Genetic analysis of primary lung interdigitating dendritic cell sarcomas. | J Pathol | 2026 | https://conductscience.org/library/papers/42092301 | PubMed |
| 42021873 | Exploiting Synthetic Lethality of PRMT5 for Precision Treatment of MTAP-Deficient Glioblastoma. | Int J Transl Med (Basel) | 2025 | https://conductscience.org/library/papers/42021873 | PubMed |
| 41899498 | Real-World Prevalence and Structural Validation of the Canonical 9p21 MTAP-CDKN2A/B Deletion in Non-NSCLC Solid Tumors. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41899498 | PubMed |
| 41891959 | MS4322 is a selective protein arginine methyltransferase 5 degrader with antitumor effects in cervical cancer cells. | Oncol Rep | 2026 | https://conductscience.org/library/papers/41891959 | PubMed |
| 41537447 | Synthetic lethality in cancer therapy: Mechanisms, models and clinical translation for overcoming therapeutic resistance. | Clin Transl Med | 2026 | https://conductscience.org/library/papers/41537447 | PubMed |
| 41487038 | Targeting of CDK1 and PRMT5 as a potential therapeutic combination for non-small cell lung cancer. | Histol Histopathol | 2026 | https://conductscience.org/library/papers/41487038 | PubMed |
| 41465382 | MTAP Deletion as a Therapeutic Vulnerability in Cancer: From Molecular Mechanism to Clinical Targeting. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41465382 | PubMed |
| 41439984 | MTAP-Null Tumors: A Comprehensive Review on Synthetic Vulnerabilities and Therapeutic Strategies. | Cells | 2025 | https://conductscience.org/library/papers/41439984 | PubMed |
| 41246302 | Immune suppression in MTAP-deficient cancers via glutamate metabolism and CXCL10 downregulation. | Front Immunol | 2025 | https://conductscience.org/library/papers/41246302 | PubMed |
| 40664803 | MTAP deficiency is highly homogeneous in advanced, muscle-invasive urothelial carcinoma of the urinary bladder. | Sci Rep | 2025 | https://conductscience.org/library/papers/40664803 | PubMed |
| 40553452 | MTA-Cooperative PRMT5 Inhibitors Are Efficacious in MTAP-Deleted Malignant Peripheral Nerve Sheath Tumor Models. | Clin Cancer Res | 2025 | https://conductscience.org/library/papers/40553452 | PubMed |
| 40240755 | Perspectives on cancer therapy-synthetic lethal precision medicine strategies, molecular mechanisms, therapeutic targets and current technical challenges. | Cell Death Discov | 2025 | https://conductscience.org/library/papers/40240755 | PubMed |
| 40227771 | Deficiency of MTAP Is Frequent and Mostly Homogeneous in Pancreatic Ductal Adenocarcinomas. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40227771 | PubMed |
| 40006625 | Understanding the Toxicity Profile of Approved ADCs. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/40006625 | PubMed |
Genes72
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37795443
GET https://conductscience.org/api/papers/v1/37795443/references?page=2